Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective

BACKGROUND: To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland. METHODS: Administrative claims processed by a major Swiss health insurer between 2005 and 2008 were analysed....

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidler, Jan, Mittendorf, Thomas, Müller, Rüdiger, von Kempis, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511873/
https://www.ncbi.nlm.nih.gov/pubmed/23021105
http://dx.doi.org/10.1186/2191-1991-2-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511873/
https://www.ncbi.nlm.nih.gov/pubmed/23021105
http://dx.doi.org/10.1186/2191-1991-2-20

Ejemplares similares